GTHX Updated Thoughts After Recent Disappointments
It's been a tough November thus far for GTHX (FIG. 1).
Why?
1) Poor revenue for approved product below guidance - flat ($8.3M) quarter over quarter; 2) Poor timing/surprising add-on stock offering and at a highly reduced price from the then current stock price; 3) Although appearing positive, Less data on readout/progress in their Phase 2 trial of Trilaciclib (COSELA) + ADC in triple negative breast cancer trial than expected/guided.
FIG. 1
See the BPIQ and Amp versions of this article for additional thoughts after subscribing. Learn more here.
11/19/22 and 11/20/22 EJV
This article is not investing or legal advice. Do your diligence before making investment decisions.
38 Views